Education
About Us
Working with TipRanks
Follow Us
XTL Biopharmaceuticals Ltd. (IL:XTLB)
:XTLB
Total Valuation
Xtl Bio has a market cap or net worth of 35.26M. The enterprise value is -2.03M.
Market Cap35.26M
Enterprise Value-2.03M
Share Statistics
Xtl Bio has 881,385,250 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding881,385,250
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Xtl Bio’s return on equity (ROE) is -0.19 and return on invested capital (ROIC) is -29.75%.
Return on Equity (ROE)-0.19
Return on Assets (ROA)-0.12
Return on Invested Capital (ROIC)-29.75%
Return on Capital Employed (ROCE)-0.34
Revenue Per Employee45.10K
Profits Per Employee-102.70K
Employee Count10
Asset Turnover0.05
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Xtl Bio is -11.69. Xtl Bio’s PEG ratio is <0.01.
PE Ratio-11.69
PS Ratio0.00
PB Ratio0.02
Price to Fair Value2.21
Price to FCF-0.07
Price to Operating Cash Flow-0.07
PEG Ratio<0.01
Income Statement
In the last 12 months, Xtl Bio had revenue of 451.00K and earned -1.03M in profits. Earnings per share was 0.00.
Revenue451.00K
Gross Profit3.00K
Operating Income-2.17M
Pretax Income-1.16M
Net Income-1.03M
EBITDA-930.00K
Earnings Per Share (EPS)0.00
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
Xtl Bio pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.20
52-Week Price Change-55.56%
50-Day Moving Average4.41
200-Day Moving Average6.19
Relative Strength Index (RSI)43.54
Average Volume (3m)474.05K
Important Dates
Xtl Bio upcoming earnings date is Dec 5, 2023, TBA Not Confirmed.
Last Earnings DateMay 31, 2023
Next Earnings DateDec 5, 2023
Ex-Dividend Date―
Financial Position
Xtl Bio as a current ratio of 0.61, with Debt / Equity ratio of 0.00%
Current Ratio0.61
Quick Ratio0.61
Debt to Market Cap0.01
Net Debt to EBITDA0.25
Interest Coverage Ratio-77.57
Taxes
In the past 12 months, Xtl Bio has paid -130.00K in taxes.
Income Tax-130.00K
Effective Tax Rate0.11
Enterprise Valuation
Xtl Bio EV to EBITDA ratio is -12.66, with an EV/FCF ratio of -7.04.
EV to Sales26.11
EV to EBITDA-12.66
EV to Free Cash Flow-7.04
EV to Operating Cash Flow-7.28
Balance Sheet
Xtl Bio has 2.34M in cash and marketable securities with $0.00 in debt, giving a net cash position of -2.34M billion.
Cash & Marketable Securities2.34M
Total Debt$0.00
Net Cash-2.34M
Net Cash Per Share>-0.01
Tangible Book Value Per Share>-0.01
Margins
Gross margin is 0.00%, with operating margin of -481.60%, and net profit margin of -227.72%.
Gross Margin0.00%
Operating Margin-481.60%
Pretax Margin-256.54%
Net Profit Margin-227.72%
EBITDA Margin-206.21%
EBIT Margin-250.33%
Analyst Forecast
The average price target for Xtl Bio is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―